Skip to main content
Premium Trial:

Request an Annual Quote

Harvard Bio Shares Slide 10.82 Percent as Revenue Inches Higher and Loss Turns to Profit

NEW YORK, May 6 (GenomeWeb News) -- Shares of Harvard Bioscience were down 10.82 percent, or $.42, at $3.46 in mid-afternoon trading after the company yesterday reported a 1-percent increase in revenues and a small net profit for the first quarter of 2005.

 

Revenues for the quarter were $22.4 million, up from $22.2 million during the same period last year. HBIO's Genomic Solutions subsidiary "continued to show improvement," according to the company. "As we have stated last quarter, we believe we have turned the corner at Genomic Solutions and are now focused on growing its revenues and profits," said CEO Chane Graziano in a company statement.

 

Research and development expenses were $1.9 million for the quarter, up from $1.7 million for the same period in 2004.

 

Net income was $200,000, or $.01 per share, compared to a net loss of $50,000, or $0 per share, during the first quarter of 2004.

 

As of March 31, HBIO had $12.4 million in cash and cash equivalents.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.